10-Q: InspireMD Reports Increased Revenue but Widening Losses in Q3 2024

InspireMD saw a revenue increase of 16.3% in Q3 2024 compared to Q3 2023, but also experienced a significant rise in net losses.

Summary

• InspireMD's revenue for the third quarter of 2024 increased to $1.81 million, a 16.3% rise from $1.56 million in the same period of 2023.
• However, the company's gross profit decreased by 5.6% to $414,000, down from $438,000 in Q3 2023.
• Operating expenses surged, with research and development costs increasing by 85.5% to $3.92 million and selling and marketing expenses rising by 68% to $1.47 million.
• General and administrative expenses also increased by 12.9% to $3.49 million.
• The company's net loss widened to $7.89 million in Q3 2024, compared to a net loss of $5.18 million in Q3 2023.
• For the nine months ended September 30, 2024, revenue increased by 13.9% to $5.06 million, but the net loss increased by 57.3% to $22.83 million.
• The company has an accumulated deficit of $244.33 million as of September 30, 2024, and faces substantial doubt about its ability to continue as a going concern.
• InspireMD is actively pursuing additional funding through equity sales, debt, strategic partnerships, and warrant exercises.

Sentiment

Score: 3

Explanation: The document highlights significant financial losses and concerns about the company's ability to continue as a going concern, despite some positive developments in clinical trials and market expansion. The overall sentiment is negative due to the financial instability and risks.

Positives

• Revenue increased by 16.3% in Q3 2024 compared to the same period in 2023, driven by growth in existing and new markets.
• The company successfully exercised Series H warrants, generating $16.9 million in net proceeds.
• The company submitted a PMA application to the FDA for the CGuard Prime carotid stent system.
• The FDA approved the company's IDE to initiate the CGUARDIANS II pivotal study.
• InspireMD established its global headquarters in Miami, Florida.

Negatives

• The company's net loss increased by 52.4% in Q3 2024 compared to Q3 2023.
• Gross profit decreased by 5.6% in Q3 2024.
• Operating expenses, particularly in research and development and selling and marketing, significantly increased.
• The company has an accumulated deficit of $244.33 million as of September 30, 2024.
• There is substantial doubt about the company's ability to continue as a going concern due to recurring losses and negative cash flows.

Risks

• The company has a history of recurring losses and negative cash flows, raising concerns about its ability to continue as a going concern.
• InspireMD needs to raise additional capital, which may be costly or difficult to obtain and could dilute existing shareholders' ownership.
• Market acceptance of the company's products is not guaranteed.
• The company faces risks related to securing and maintaining regulatory approvals.
• Negative clinical trial results or product delays could impact the company's prospects.
• The company is dependent on a single manufacturing facility in Israel, which is subject to geopolitical risks.
• The company faces intense competition in the medical device industry.
• The company's operations are subject to foreign currency exchange rate fluctuations and political and economic instability in various jurisdictions.
• The ongoing conflict in Israel could disrupt the company's operations and supply chain.

Future Outlook

The company anticipates potential FDA approval of the CGuard Prime stent system in the first half of 2025 and is seeking strategic partners for a potential launch in Japan and other Asian countries. The company also plans to explore new indications for CGuard and is developing the SwitchGuard neuroprotection system.

Management Comments

• Management plans include the continued commercialization of the company's product and raising capital through the sale of additional equity securities, debt or capital inflows from strategic partnerships and exercise of warrants.
• Management has concluded that there is substantial doubt about our ability to continue as a going concern.

Industry Context

The company operates in the competitive medical device industry, focusing on the treatment of carotid artery disease. The expansion of Medicare coverage for carotid artery stenting (CAS) in the U.S. has significantly increased the addressable market for the company's products. The company is also developing a new transcarotid artery revascularization (TCAR) system, SwitchGuard neuroprotection system (SwitchGuard NPS), for transcarotid access and neuro protection.

Comparison to Industry Standards

• The company's C-GUARDIANS trial results are being compared to performance goals based on previous pivotal stent trials, which are considered industry standards.
• The company's 30-day DSMI rate of 0.95% and one-year rate of 1.95% are being evaluated against these benchmarks.
• The company is aiming to establish the CGuard Carotid Stent System as a viable alternative to vascular surgery, competing with both carotid artery stenting and carotid endarterectomy procedures.

Related Party Transactions

• A member of the CEO's immediate family provided administrative services in connection with the company's expansion to the U.S. for $55,000 during the nine months ended September 30, 2024, and $25,000 during the three months ended September 30, 2024.

Stakeholder Impact

• Shareholders face the risk of dilution due to potential equity raises and the risk of loss due to the company's financial instability.
• Employees may be affected by potential cost-cutting measures or changes in operations due to the company's financial situation.
• Customers may be impacted by potential disruptions in supply or changes in product availability.
• Suppliers may face risks related to the company's ability to pay for goods and services.
• Creditors face risks related to the company's ability to repay debts.

Next Steps

• The company plans to continue commercializing its products.
• The company will continue to seek additional funding.
• The company will pursue regulatory approvals for its products.
• The company will continue to develop new products and indications.
• The company will monitor the security situation in Israel and its potential impact on operations.

Key Dates

Keywords

medical devices, carotid artery disease, stent, MicroNet, CGuard EPS, CGuard Prime, FDA, PMA, clinical trial, vascular, stroke, IDE, warrants, equity, financing